Changes in U.S. medical school conflict of interest policies from 2014 to 2023
Shamik Bhat, Devika A. Shenoy, Magda Wojtara, Alissa Kainrath, Oak Sonfist, Jantzen Faulkner, Brianna Wang, Linnea Wilson, Timothy S. Anderson, Avanti Dey, Ramya Iyadurai, Ramya Iyadurai, Ramya Iyadurai

TL;DR
This study compares conflict of interest policies at top U.S. medical schools in 2023 to those in 2014, finding that most policies still fall short of recommended standards.
Contribution
The study evaluates and compares COI policies across 30 top U.S. medical schools using a standardized scoring system from 2014 to 2023.
Findings
Most schools had strong policies on enforcement, gift acceptance, and ghostwriting, but none had model policies for limiting direct faculty payments.
Over half of the schools saw a decrease in COI policy scores from 2014 to 2023.
Faculty at all schools accepted industry payments, including many deans and clerkship directors.
Abstract
Concerns about the influence of the pharmaceutical industry on medical education, ranging from education of students to professional development, have led professional societies to recommend regulation of interactions between industry and medical schools. The objective of this study was to evaluate conflict of interest (COI) policies at medical schools in 2023 compared to 2014. This study used a cross-sectional design to evaluate the COI policies at the top 30 medical schools identified by US News and World Report rankings. The authors collected policies by survey and review of public websites, and assessed their quality across 15 domains informed by guidelines published by leading national organizations and previous PharmFree Scorecards. Each domain was graded on a 3-level scale derived from professional organization guidelines, which when totaled corresponded to the following letter…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical industry and healthcare · Healthcare Systems and Challenges · Healthcare cost, quality, practices
